<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>KFF Health News</provider_name><provider_url>https://kffhealthnews.org</provider_url><author_name>khnlaureno</author_name><author_url>https://kffhealthnews.org/news/author/khnlaureno/</author_url><title>Anti-Overdose Naloxone Could Soon Be OTC As FDA Fast-Tracks Review - KFF Health News</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="Tbdz1h0MAD"&gt;&lt;a href="https://kffhealthnews.org/morning-breakout/anti-overdose-naloxone-could-soon-be-otc-as-fda-fast-tracks-review/"&gt;Anti-Overdose Naloxone Could Soon Be OTC As FDA Fast-Tracks Review&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://kffhealthnews.org/morning-breakout/anti-overdose-naloxone-could-soon-be-otc-as-fda-fast-tracks-review/embed/#?secret=Tbdz1h0MAD" width="600" height="338" title="&#x201C;Anti-Overdose Naloxone Could Soon Be OTC As FDA Fast-Tracks Review&#x201D; &#x2014; KFF Health News" data-secret="Tbdz1h0MAD" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>An over-the-counter version of Emergent BioSolution's overdose reversal nasal spray could be on sale as early as March. Separately, AP reports that the FDA's speedy approval processes have been slowed by scrutiny.</description></oembed>
